Nuvalent Investor Presentation Deck
August 2023, 39 slides
  1. Nuvalent
  2. Related Decks
  3. Investor Presentation Decks
corporate overview august | Nuvalent
| Nuvalent
| Nuvalent
vision discover develop deliver ones | Nuvalent
the team i | Nuvalent
targeted therapies for patients with cancer resistance | Nuvalent
kinase resistance | Nuvalent
kinase selectivity a | Nuvalent
for positive advanced and other solid tumors | Nuvalent
positive market overview | Nuvalent
| Nuvalent
overcoming kinase selectivity in | Nuvalent
preclinical exhibits potent activity across diverse fusion partners and resistance mutations | Nuvalent
preclinical is a brain penetrant selective inhibitor with the potential to avoid related adverse events | Nuvalent
study design a global phase study of in patients with advanced positive and other solid tumors | Nuvalent
cohort accrual phase dose | Nuvalent
phase population heavily solid tumors | Nuvalent
preliminary safety profile favorable and consistent with the highly selective sparing design of | Nuvalent
exposure exceeded predicted efficacy thresholds | Nuvalent
preliminary efficacy induced tumor response across heavily patient populations | Nuvalent
preliminary efficacy radiographic tumor regression observed across all dose levels | Nuvalent
time on treatment sustained duration with follow up ongoing | Nuvalent
resistance mutations induced rapid responses in resistant patients with tumor | Nuvalent
activity induced responses in intracranial lesions | Nuvalent
case study intracranial and extracranial activity in refractory ase refractory | Nuvalent
| Nuvalent
for alk positive advanced and other solid tumors | Nuvalent
alk positive market overview | Nuvalent
| Nuvalent
preclinical is a brain penetrant alk selective inhibitor with the potential to avoid related adverse events | Nuvalent
preclinical induced tumor regression across models of diverse alk single and compound resistance mutations | Nuvalent
| Nuvalent
for malignancies driven by her exon insertion mutations her | Nuvalent
preclinical is a brain penetrant her selective kinase inhibitor with potential to avoid adverse events related to inhibition | Nuvalent
pipeline expansion | Nuvalent
pipeline expansion | Nuvalent
pipeline ongoing programs | Nuvalent
| Nuvalent
| Nuvalent
See More
Nuvalent
Investor Presentation Decks
Biotechnology Decks
Healthcare Decks
Explore Topics
Preclinical
Tumor
Inhibitor
Cancer
Solid tumor
Recent decks by Nuvalent
Investor Presentation
April 2024
Investor Presentation
February 2024
Investor Presentation
January 2024
Investor Presentation
January 2024
See all presentations by Nuvalent (10 decks)
Related decks
Nuvectis Pharma
Investor Presentation
August 2023
Erasca
Investor Presentation
August 2023
Erasca
Investor Presentation
November 2023
Nuvectis Pharma
Investor Presentation
July 2023
Nuvectis Pharma
Investor Presentation
January 2024
Alkermes
Investor Day
March 2021
Fusion Pharmaceuticals
Investor Presentation
January 2024
Immatics
Results
October 2022
Recent decks by Nuvalent
See all presentations (10 decks)
Investor Presentation
April 2024
Investor Presentation
February 2024
Investor Presentation
January 2024
Investor Presentation
January 2024
Nuvectis Pharma
Investor Presentation
August 2023
Erasca
Investor Presentation
August 2023
Erasca
Investor Presentation
November 2023
Nuvectis Pharma
Investor Presentation
July 2023
Nuvectis Pharma
Investor Presentation
January 2024
Alkermes
Investor Day
March 2021
Fusion Pharmaceuticals
Investor Presentation
January 2024
Immatics
Results
October 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights